Proteona featured as a “one to watch” in the inaugural Spinoff Prize by Nature Research and Merck
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
SINGAPORE, 30 June 2020 - Proteona has been selected by the Spinoff Prize as one of the 44 top science-based spinoff companies from around the world. The Spinoff Prize is established by Nature Research in partnership with Merck. The award highlights spinoffs who take top-quality scientific research to the market and make a positive impact.
Proteona is recognized for addressing the clinical need in multiple myeloma, a blood cancer that is difficult to treat. Different patients, or even tumor clones within the same patient, may respond to drug treatment differently. Choosing the right drug is challenging. Proteona uses single cell proteogenomics and artificial intelligence-assisted algorithms to measure tumor cell diversity in patient biopsy, which can help clinicians choose the best treatment for individual patients.
“It is a great honour to be recognized by the Spinoff Prize award, issued by Nature research, who represents the top scientific standard, and by Merck, an industry leader well known for its accelerator programs and technology innovation.” Said Dr. Andreas Schmidt, CEO of Proteona. “It adds credibility to the science and business we are doing at Proteona, and provides momentum for us to achieve the next milestones. This comes just at the right moment for our upcoming fundraising campaign, which will be launched in a few weeks’ time.”
Proteona is one of the three Asia-based companies who made it to the prestigious list.
The Spinoff Prize application was open to all spinoff companies worldwide from fields of pharmaceuticals, agriculture, chemicals and digital technology. The companies were selected by a judging panel consisting of experts from Nature Reseach, Merck, and M Ventures. All companies were evaluated in five criteria: the science, the opportunity, the plan, the team, and the impact.
Proteona is committed to improving the clinical outcome of multiple myeloma. Proteona has recently been chosen by Amgen as part of the Start-ups Meets Pharma program to improve multiple myeloma treatment selection.
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.